secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001628280-25-051603
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell reports Q3 net loss $38.8M, cash $320M; acquires LYL273 CAR T for mCRC with 67% ORR
--------------------------------------------------------------------------------

- Net loss $38.8M vs $44.6M YoY; non-GAAP net loss $29.1M.
- Cash $320M, expected to fund pipeline into 2027.
- Acquired exclusive global rights to LYL273 (GCC-targeted CAR T) from ICT; Phase 1 data: 67% ORR at highest dose in refractory mCRC.
- FDA granted RMAT designation for ronde-cel in 2L LBCL; PiNACLE-H2H Phase 3 trial expected to start by early 2026.
- Two ronde-cel abstracts accepted for oral presentation at ASH 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828025051603/0001628280-25-051603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828025051603/lyel-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-051603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer